RYTM News and Press, Rhythm Pharmaceuticals Inc. From 06/13/22

-- Sustained weight loss observed following 18 to 36 months on therapy -- -- Setmelanotide shown to be well-tolerated for up to three years of treatment -- -- Data support continued efficacy and long-term use of setmelanotide in patients with BBS or POMC or LEPR deficien...

-- Continued reductions in BMI observed following one year of setmelanotide treatment in patients with SH2B1 or SRC1 deficiency obesities or POMC or LEPR insufficiency obesities (heterozygous) -- -- Long-term reductions in BMI support probability of success in ongoing pivotal Ph...

Reviewing its coverage on biotechs with negative enterprise values, Morgan Stanley says that the number of companies on the list with potential catalysts in 2022 has increased to 27 in May from 20 previously. Adding market capitalization to total debt and deducting cash and cash equivalents, ...

BOSTON, May 04, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare genetic diseases of obesity, today announced that David Meeker, M.D., Chair, Chief Executive Offic...

The following slide deck was published by Rhythm Pharmaceuticals, Inc. in conjunction with their 2022 Q1 earnings call. For further details see: Rhythm Pharmaceuticals, Inc. 2022 Q1 - Results - Earnings Call Presentation

Rhythm Pharmaceuticals, Inc. (RYTM) Q1 2022 Earnings Conference Call May 03, 2022 08:30 AM ET Company Participants David Connolly - Investor Relations and Corporate Communications David Meeker - Chair, President and Chief Executive Officer Jennifer Chien - Executive Vice President, Head of No...

Rhythm Pharmaceuticals press release (NASDAQ:RYTM): Q1 GAAP EPS of -$1.05 misses by $0.04. Revenue of $1.49M as compared to $35.0 thousand for the first quarter of 2021. As of March 31, 2022, cash, cash equivalents and short-term investments were approximately $241.0 million, a...

-- Patient identification and physician engagement ongoing in preparation for U.S. commercial launch in June 2022 in BBS and Alström syndrome, pending FDA approval -- -- First commercial patients treated with IMCIVREE ® (setmelanotide) in France under paid ...

Rhythm Pharmaceuticals (NASDAQ:RYTM) is scheduled to announce Q1 earnings results on Tuesday, May 3rd, before market open. The consensus EPS Estimate is -$1.04 and the consensus Revenue Estimate is $2.3M (+5650.0% Y/Y). Over the last 3 months, EPS estimates have seen 1 upward revision an...

-- New data show setmelanotide treatment led to clinically meaningful improvements in lipid parameters, without affecting blood pressure or heart rate in patients with BBS -- -- Additional posters include data from pediatric and adolescent patients enrolled in Phase 3 trial in B...